Clinical trials: Cervical Cancer Stage IIa
Esophageal Cancer
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00655876
- Testing
- cetuximab, cisplatin, paclitaxel
- Where
- 175 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Radiation Therapy Oncology Group
Cervical Cancer
A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16 and/or 18-positive cervical carcinoma.
- Trial name
- NCT02172911
- Testing
- INO-3112, CELLECTRA™-5P
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Inovio Pharmaceuticals
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
This randomized phase III trial is studying cisplatin, radiation therapy, and tirapazamine to see how well they work compared to cisplatin and radiation therapy in treating patients with cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer
- Trial name
- NCT00262821
- Testing
- cisplatin, tirapazamine
- Where
- 282 sites in United States, Canada
- Volunteers
- 402 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer
RATIONALE: Diagnostic procedures, such as fluorine F 18 EF5 PET/CT imaging, may help find oxygen in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00978874
- Testing
- fludeoxyglucose F 18, fluorine F 18 EF5
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with cervical cancer has spread from where it started to…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7
- Trial name
- NCT01414608
- Testing
- Brachytherapy, Carboplatin, Cisplatin
- Where
- 326 sites in United States, Canada and 3 more
- Volunteers
- 926 people
- Sponsor
- GOG Foundation
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
This phase II trial is studying how well giving bevacizumab together with radiation therapy and cisplatin works in treating patients with previously untreated locally advanced cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7
- Trial name
- NCT00369122
- Testing
- Bevacizumab, Cisplatin, External Beam Radiation Therapy
- Where
- 106 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Uterine Cervical Cancer
Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
The purpose of this study is first to establish what is the ideal dose of gemcitabine, a chemotherapy agent, when given in combination with radiation.
- Trial name
- NCT00184093
- Testing
- Gemcitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
This phase II trial is studying how well giving panitumumab, combination chemotherapy, and radiation therapy together before surgery works in treating patients with advanced esophageal or gastroesophageal (GE) junction cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Adenocarcinoma, Stage IIA Esophageal Cancer, Stage IIB Esophageal Cancer
- Trial name
- NCT01307956
- Testing
- Fluorouracil, Laboratory Biomarker Analysis, Leucovorin Calcium
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Cervical Cancer
Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer
RATIONALE: Diagnostic procedures, such as 64Cu-labeled diacetyl-bis[N4-methylthiosemicarbazone] (copper Cu 64-ATSM) PET/CT scans, may help doctors predict how patients will respond to treatment.
- Trial name
- ACRIN6682 (NCT00794339)
- Testing
- 64Cu-ATSM, FDG
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- American College of Radiology
Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
This phase II trial is studying how well PET scans using fluoromisonidazole F 18 and fludeoxyglucose F 18 work in finding oxygen in tumor cells of patients undergoing treatment for newly diagnosed stage 1B, stage II, stage II, or…
- Conditions
- Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer
- Trial name
- NCT00559377
- Testing
- 18F-fluoromisonidazole, fluorodeoxyglucose F 18, positron emission tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
RATIONALE: PET scans done during chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT01333033
- Testing
- Oxaliplatin, Leucovorin Calcium, Fluorouracil
- Where
- 68 sites in United States
- Volunteers
- 257 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
This randomized phase III trial studies radiation therapy with chemotherapy to see how well they work compared to radiation therapy alone in treating patients with stage I-IIA cervical cancer who previously underwent surgery.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage I Cervical Cancer AJCC v6 and v7
- Trial name
- NCT01101451
- Testing
- Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy
- Where
- 719 sites in United States, Japan and 1 more
- Volunteers
- 340 people
- Sponsor
- GOG Foundation
Lung Cancer, Tobacco Use Disorder
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population.
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer
- Trial name
- NCT01434342
- Testing
- Nicotine Replacement Patch
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Wake Forest University Health Sciences